Evaluation of a Commercial Rapid Molecular Point-of-Care Assay for Differential Diagnosis Between SARS-CoV-2 and Flu A/B Infections in a Pediatric Setting
Viruses,
Journal Year:
2024,
Volume and Issue:
16(10), P. 1638 - 1638
Published: Oct. 20, 2024
Given
the
ongoing
COVID-19
pandemic,
there
is
a
need
to
identify
SARS-CoV-2
and
differentiate
it
from
other
respiratory
viral
infections,
especially
influenza
A
B,
in
various
critical
settings.
Since
their
introduction,
use
of
rapid
antigen
tests
has
spread
worldwide,
but
variability
diagnostic
accuracy.
In
present
study,
we
evaluated
clinical
performance
ID
NOW™
2.0,
molecular
point-of-care
test
(POCT)
based
on
enzymatic
isothermal
amplification
for
differential
diagnosis
A/B
pediatric
emergency
setting.
cohort
patients
admitted
between
December
2022
February
2023
were
simultaneously
tested
with
POCT
standard
laboratory
assay.
Our
findings
showed
high
negative
agreement
assay
across
different
age
groups
SARS-CoV-2,
A,
B
(more
than
98.0%),
while
its
positive
varied
significantly
abovementioned
species
50.0%
100%.
These
results
highlight
potential
2.0
as
reliable
tool
excluding
infections
symptomatic
patients,
although
variable
suggests
confirmatory
RT-qPCR
testing
certain
epidemiological
settings
order
ensure
accurate
appropriate
patient
management.
Language: Английский
Application of a SARS-CoV-2 Antigen Rapid Immunoassay Based on Active Microfluidic Technology in a Setting of Children and Young Adults
Viruses,
Journal Year:
2023,
Volume and Issue:
16(1), P. 41 - 41
Published: Dec. 26, 2023
To
carry
out
effective
and
quick
identification
of
SARS-CoV-2
from
nasopharyngeal
swabs
contain
outbreaks,
reliable
rapid
tools
are
needed.
Herein,
we
compared
a
antigen
test
based
on
active
microfluidic
technology
to
an
RT-qPCR
assay
in
pediatric
young
adult
patients
admitted
the
Pediatric
Emergency
Unit
Children’s
Hospital.
Nasopharyngeal
collected
with
suspected
COVID-19
disease
those
without
related
symptoms,
but
requiring
hospitalization,
were
performed
both
assays.
We
included
375
median
age
5
years
study,
estimated
overall
prevalence
7.2%.
Overall,
observed
specificity
97.4%
(95%
CI:
94.9–98.7)
sensitivity
66.6%
46.0–82.7)
positive
likelihood
ratio
(LR+)
25.8
12.8–51.8).
In
subgroup
symptomatic
patients,
95.2%
89.4–98.0)
80.0%
44.2–96.5)
respectively;
LR+
was
16.6
7.19–38.6).
asymptomatic
subset,
performance
showed
98.7%
95.8–99.7),
58.8%
33.5–80.6),
43.7
13.3–144.0).
Compared
RT-qPCR,
new
microfluidic-based
higher
(>95%)
population,
thus
representing
suitable
point-of-care
testing
(POCT)
clinical
setting
low
COVID-19.
Language: Английский